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Abstract
Objectives
Assessment of regional pediatric last-resort antibiotic utilization patterns is hampered by
potential confounding from population differences. We developed a risk-adjustment model
from readily available, internationally used survey data and a simple patient classification to
aid such comparisons.
Design
We investigated the association between pediatric conserve antibiotic (pCA) exposure and
patient / treatment characteristics derived from global point prevalence surveys of antibiotic
prescribing, and developed a risk-adjustment model using multivariable logistic regression.
The performance of a simple patient classification of groups with different expected pCA
exposure levels was compared to the risk model.
Setting
226 centers in 41 countries across 5 continents.
Participants
Neonatal and pediatric inpatient antibiotic prescriptions for sepsis/bloodstream infection for
1281 patients.
Results
Overall pCA exposure was high (35%), strongly associated with each variable (patient age,
ward, underlying disease, community acquisition or nosocomial infection and empiric or tar-
geted treatment), and all were included in the final risk-adjustment model. The model dem-
onstrated good discrimination (c-statistic = 0.83) and calibration (p = 0.38). The simple
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classification model demonstrated similar discrimination and calibration to the risk model.
The crude regional pCA exposure rates ranged from 10.3% (Africa) to 67.4% (Latin Amer-
ica). Risk adjustment substantially reduced the regional variation, the adjusted rates ranging
from 17.1% (Africa) to 42.8% (Latin America).
Conclusions
Greater comparability of pCA exposure rates can be achieved by using a few easily col-
lected variables to produce risk-adjusted rates.
Introduction
Antibiotics are among the most commonly used medications for hospitalized children [1]. On
any day, 30% to 60% of children admitted to hospital around the world will receive at least one
antibiotic, with many being prescribed multiple systemic antimicrobials [2,3].
Antimicrobial stewardship interventions can improve antibiotic use in this vulnerable pop-
ulation and are usually implemented at a high level of aggregation, for example at hospital
level [4,5]. It is often desirable to compare the use of antibiotics, especially of last-resort agents,
between hospitals or regions to identify outliers and therefore areas for intervention. However,
merely comparing the overall volume of use or crude proportions for antibiotics of interest is
unlikely to be useful because prescription patterns vary markedly, and this is partially due to
differences in patient case-mix [6–11].
In many areas of infection control, regression models are used to adjust metrics for differ-
ences in patient case-mix [12–14]. However, these risk-adjustment models can easily become
complex, may be based on specific data that are not widely available and/or comparable, and
can require the adoption of extensive, costly data collection processes.
Another method is to apply a stratification system and examine exposure within groups of
similar patients. An example of this method from another area of medical practice is the Rob-
son classification, which stratifies pregnant women according to simple and widely available
clinical characteristics that influence their a priori risk of having a Caesarean delivery [15–17].
We examined whether a risk-adjustment model could be developed from readily available
variables that would facilitate the fair comparison of statistics from point prevalence surveys
(PPS) on the prescribing of antibiotics to children with sepsis/bloodstream infections. We
focused on three “pediatric conserve antibiotics” (pCAs) for severe Gram-negative and Gram-
positive neonatal and pediatric infections. These antibiotics are part of the newly defined World
Health Organization Watch group of antibiotics. This group has been identified to have a higher
resistance potential, and should only be used for specific indications or in infections caused by
bacteria suspected or proven to be resistant to less broad-spectrum options [18]. We evaluated
whether available variables enabled the creation of: (i) a risk-adjustment model to fairly compare
the prevalence rates across world regions, and (ii) a simple stratification system that identified
patient groups who would be expected to have similar exposures due to their characteristics.
Materials and methods
Data collection
The study used data collected as part of the Antibiotic Resistance and Prescribing in European
Children (ARPEC) project global PPS [3]. PPS are simple, standardized tools used widely
internationally to collect data on antimicrobial use to facilitate monitoring within centers and
Risk-adjusted hospital pediatric antibiotic use
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countries [19]. Participating centers were asked to conduct a one-day cross-sectional survey of
antimicrobial prescriptions for inpatients on neonatal and pediatric wards during three peri-
ods in 2011/2012 [2,3]. During each PPS all neonatal and pediatric wards in participating insti-
tutions had to be surveyed once within the defined auditing period. All patients present in the
wards at 8:00 am, and at least since midnight on the day of the survey, were recorded. For each
patient treated with at least one antimicrobial, detailed data on the prescription as well as
about the patient were collected according to a standardized protocol.
The ARPEC PPS were conducted in 226 participating centers located in 41 countries,
which were grouped into continental regions (Africa, Asia, Australia, Europe–East, Europe–
North, Europe–South, Europe-West, Latin/South America and North America) according to
the UN geoscheme classification [2,3].
The PPS methodology and data collection approaches have previously been described in
detail [2,3]. During data collection no unique identifiers, such as hospital numbers or dates of
birth, were recorded. As the PPS was therefore a completely anonymized audit of antimicro-
bial prescribing to inpatient neonates and children, formal ethical review was not a require-
ment. Individual participating centres were asked to ascertain any local requirements for
ethical review. By entering data, centres confirmed that they had taken the required steps
according to their local and national regulatory and legal requirements.
Study population and definition of patient and treatment characteristics
The study used the records of surveyed patients who were prescribed systemic antibiotics (J01)
[20] for the most common indication of suspected or definitive sepsis/bloodstream infection
[3], excluding febrile neutropenia and catheter-related bloodstream infection. A single key
infection syndrome was selected as different factors may drive prescribing of antibiotics
depending on the type of infection being treated. Relevant prescriptions were identified from
the PPS information on “reason for prescription”.
In terms of antibiotic use, we focused on carbapenems (J01DH), glycopeptides (J01XA) and
linezolid (J01XX08). Prescribing of these antibiotics may reflect actual or feared infection
caused by resistant organisms, such as extended-spectrum beta-lactamase producing Gram-
negative bacteria or methicillin-resistant Staphylococcus aureus. The World Health Organiza-
tion confirms these antibiotics, among others, as key targets for national antibiotic stewardship
[18]. Our study is limited to the indicated groups and follows the same approach as a recent
study evaluating the impact of antimicrobial stewardship on antibiotic prescribing in US chil-
dren’s hospital [21]. Exposure to pCAs was defined at the patient level, with a patient classified
as exposed if one or more of the antibiotics listed above was prescribed.
At the patient level, the ARPEC dataset included information on a patient’s age, whether
they had any chronic conditions, and the type of ward the patient was on. Data were also col-
lected on the type of prescription (empiric or targeted). Neither the microbiological results for
individual patients nor hospital antibiograms were available. Finally, timing of prescription
was available as having been issued >48 hours after hospitalization (hospital-acquired) or48
hours after hospitalization (community-acquired). Any prescription for sepsis/bloodstream
infection in the first three days of life was considered neonatal early onset sepsis. Wards were
classified as either a neonatal intensive care unit (NICU, all care levels), pediatric intensive
care unit (PICU) or other pediatric wards. Patients with any recorded underlying disease from
a predefined list including surgical malformations, chronic neurological, gastrointestinal,
endocrine, lung and renal disease as well as congenital heart disease, oncologic/hematologic
diseases, genetic or metabolic disorders, rheumatological or autoimmune disease and chronic
infections were labeled as having underlying disease (S1 File). Patients receiving any targeted
Risk-adjusted hospital pediatric antibiotic use
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prescriptions for a sepsis/bloodstream infection (according to the ARPEC protocol based on
pathogen identification and/or antimicrobial susceptibility testing) were defined as receiving
targeted treatment, even when additional prescriptions were empiric. All other patients were
labeled as receiving empiric treatment.
Statistical analysis
Logistic regression was used to assess the association between pCA exposure and the individ-
ual patient and treatment characteristics. Age was dichotomized into neonates aged 3 days or
younger versus infants aged 4 days or older and children (reflecting clinical differences
between early-onset and late-onset sepsis among neonates).
We then developed a risk model using multivariable logistic regression.
The model was developed by sequentially adding each available patient variable, starting
with the variable that had the strongest univariate association and ending with the weakest. A
Wald test was used to assess the contribution of an added variable to the model and a p value
of 0.05 was used as the threshold for inclusion. Following this, interactions between included
variables were explored. The performance of the model was assessed in terms of its calibration
and discrimination. Calibration describes the level of agreement between the predicted and
observed risks, and was evaluated using the Hosmer-Lemeshow test. Discrimination indicates
the ability of a model to distinguish patients with a lower and higher risk of pCA prescription.
We evaluated this by using the c-statistic (equivalent to the Area under the ROC curve).
The regression model was used to calculate risk-adjusted regional pCA exposure rates.
These were derived using indirect standardization, which involved multiplying the ratio of
observed/expected exposure rates by the mean exposure rate in the whole cohort [9]. Approxi-
mate 95% confidence intervals were derived for proportions and indirectly standardized rates
using the Wilson Score and Byar’s Method, respectively.
As a sensitivity analysis, we repeated the above process using a multilevel logistic model,
which incorporated a random-intercept term for the subregions as well as the explanatory var-
iables. This accounted for any lack of independence in the data due to patients being clustered
within subregions.
Finally, a small number of mutually exclusive and comprehensive patient subgroups were
defined on the basis that they described clinical situations in which we would expect a patient’s
chance of receiving pCA to be similar given the seriousness of the situation and the effective-
ness of current antiobiotics. We used the same variables that were considered in the risk-
model development process because they represented information that is easy to collect and
can be standardized. Inspection of the variables identified six patient groups that were
expected to be associated with different levels of exposure to pCA:
1) Neonatal early onset sepsis (infants3 days of age): High reported coverage provided by
narrow-spectrum regimens [22].
2) Community-acquired sepsis in otherwise healthy infants >3 days of age and children:
Lower levels of colonization and infection by multidrug-resistant pathogens [23].
3) Community-acquired sepsis in infants>3 days of age and children with underlying disease:
Colonization by multidrug-resistant pathogens possible with reported epidemiology simi-
lar to hospital-acquired bloodstream infection [23].
4) Empiric treatment of hospital-acquired sepsis in infants and children of any age outside of
PICU: Colonization by multidrug resistant pathogens possible, but colonization pressure
less than in intensive care [24].
Risk-adjusted hospital pediatric antibiotic use
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5) Targeted treatment of hospital-acquired sepsis in infants and children of any age outside of
PICU: May include patients having been discharged from intensive care to complete treat-
ment after stabilization, therefore likely to partially reflect intensive care epidemiology [25].
6) Hospital-acquired sepsis in infants and children of any age in PICU: Colonization by multi-
drug-resistant bacteria expected with high colonization pressure in intensive care [25].
We examined the ability of these subgroups to reduce the heterogeneity within the patient
population using the measures of discrimination and calibration described above. All statistical
analyses were carried out using Stata/IC 13.11, Statacorp, USA.
Results
Description of cohort
The complete global ARPEC PPS cohort contained data on 11899 prescriptions on 6499
patients. Among these, there were 2668 prescriptions for sepsis, but limiting the cohort to
patients with complete records led to the exclusion of a further 415 prescription records (Fig
1). The final dataset contained 2253 systemic antibiotic prescriptions for 1281 infants and chil-
dren, representing 19% of a total of 11899 recorded prescriptions.
Overall pCA exposure
Of the 1281 included patients, 445 patients (34.7%; 159 children30 days of age of which two
were3 days of age, 286 children >30 days of age) were exposed to pCAs. In total, 18.4%
(235/1281) were receiving carbapenems, 25.4% (325/1281) glycopeptides and 1.2% (16/1281)
linezolid. For each of the patient and treatment characteristics, the proportion of exposed
patients varied across the levels of each variable by at least 10%, as shown in Table 1.
Multivariable logistic regression model for exposure to pCA
Each individual patient and treatment characteristic was found to be associated with antibiotic
use, and improved the performance of the multivariable logistic model when added (Table 1).
There was evidence of an interaction between the variables “ward” and “acquisition of infec-
tion” as well as between the variables “underlying disease” and “type of treatment”. These sepa-
rate variables were replaced by variables that captured the combination of categories. Table 2
shows the results of the model that takes into account these interactions. Overall, the following
were associated with increased odds of pCA exposure: (1) presence of any underlying disease,
(2) treatment in PICU; (3) receiving targeted treatment; (4) treatment for hospital-acquired
infection. Being3 days old was associated with lower odds of pCA exposure.
This final model demonstrated strong discrimination, with a c-statistic of 0.83. There was also
evidence of good calibration (Hosmer-Lemeshow test, p = 0.38, see Fig 2 for calibration plot).
Multilevel random-intercept logistic model for exposure to pCA
The analysis using the multilevel model gave similar results to the main analysis. We found
only modest variation in the random-intercepts of the subregions (variance = 0.21; SE(var) =
0.14) and the coefficients of the explanatory variables were similar to those estimated in the
standard model. In addition, the Pearson correlation coefficient between the predicted risks
for individuals from the two models was 0.97, with the predictions from the multilevel model
producing to almost identical calibration and discrimination figures.
Risk-adjusted hospital pediatric antibiotic use
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Adjusted regional patterns of pCA exposure
Fig 3 demonstrates the impact of using the risk model to adjust for differences in patient char-
acteristics on regional pCA exposure levels. Crude regional exposure rates ranged from 10.3%
(Africa) to 67.4% (Latin America). After adjustment, there was substantially less variation
between the regions, with the adjusted regional exposure rates ranging from 17.1% (Africa) to
42.8% (Latin America). The 95% confidence intervals around adjusted pCA exposure rates
Fig 1. Flow chart of prescription and patient inclusion.
https://doi.org/10.1371/journal.pone.0199878.g001
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indicate that, with the exception of Africa, regional estimates may not differ from the overall
cohort mean pCA exposure level once key characteristics have been taken into account.
pCA exposure in predefined groups
Table 3 shows the characteristics of the six patient groups that were derived from clinical
reasoning.
Table 4 shows the distribution of patient groups by region.
Overall, nearly 50% of children fell into groups 4 to 6, as they were being treated for hospi-
tal-acquired sepsis/bloodstream infection. In terms of the pCA exposure rates, levels were
Table 1. Association of key patient characteristics with exposure to pCA antibiotics (group comparisons usingΧ2 testing).
Total patients with sepsis/BSI % in group pCA-exposed % exposed p-value
Age
Neonate3 days of age 123 9.6 2 1.6 p<0.001
Infant or child >3 days of age 1158 90.4 443 38.3
Ward
Pediatric ward 466 36.4 117 25.1 p<0.001
Neonatal intensive care 635 49.6 219 34.5
Pediatric Intensive care 180 14.1 109 60.6
Underlying disease
Absent 311 24.3 32 10.3 p<0.001
Present 970 75.7 413 42.6
Acquisition of infection
Community 649 50.7 78 12.0 p<0.001
Hospital 632 49.3 367 58.0
Type of treatment
Empiric 980 76.5 285 29.1 p<0.001
Targeted 301 23.5 160 53.2
Total 1281 445 34.7
https://doi.org/10.1371/journal.pone.0199878.t001
Table 2. Logistic regression results showing adjusted odds ratios for exposure to pediatric reserve antibiotics
(pCAs) with 95% confidence intervals.
Group Adjusted OR 95%CI
Patients according to ward type and acquisition of infection
Non-ICU / community-acquired Ref -
Non-ICU / hospital-acquired 5.0 3.0–8.3
NICU / community-acquired 0.6 0.3–1.1
NICU / hospital-acquired 5.7 3.7–8.8
PICU / community-acquired 4.2 2.2–8.1
PICU / hospital-acquired 12.7 7.3–22.2
Patients according to underlying disease and type of prescription
No underlying disease / empiric Ref -
No underlying disease / targeted 4.3 1.8–10.0
Underlying disease / empiric 3.8 2.2–6.7
Underlying disease / targeted 7.1 3.9–13.0
Patients according to age
Neonate3 days of age Ref -
Neonate >3 days of age, infant or child 16.9 4.0–70.9
https://doi.org/10.1371/journal.pone.0199878.t002
Risk-adjusted hospital pediatric antibiotic use
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Fig 2. Calibration plot for logistic regression risk model of pCA exposure.
https://doi.org/10.1371/journal.pone.0199878.g002
Fig 3. Crude and risk adjusted regional exposure rates for pediatric reserve antibiotics. Bars correspond to crude rates, squares to adjusted rates (shown with 95%
confidence intervals). Data for Eastern Europe have been omitted due to low number of patients surveyed (n = 17) The horizontal line indicates the mean pCA exposure
rate in the whole cohort. Patient numbers for each region are shown at the bottom of each bar.
https://doi.org/10.1371/journal.pone.0199878.g003
Risk-adjusted hospital pediatric antibiotic use
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lowest in neonates treated for early onset sepsis (1.6%) and highest in patients with hospital-
acquired sepsis on PICU (75.0%). We assessed the performance of this simple classification by
using a logistic regression model that included only these six predefined groups. The model
had a similar level of performance as the full risk model, with good levels of discrimination
(c-statistic = 0.81) and calibration (Hosmer-Lemeshow test, p = 0.813; Fig 4). The regional dis-
tribution of patients may explain very high crude pCA exposure levels in Latin America:
Nearly 80% of patients in this region fell into groups 4 to 6 compared with maximally 50–60%
in other regions. These patients would be expected to have higher pCA exposure rates than
patients in groups 1 to 3.
Discussion
The data from global point prevalence surveys of inpatient neonatal and pediatric systemic
antibiotic prescriptions for sepsis/bloodstream infection revealed large differences in the crude
pCA prevalence rates across the regions. But, the interpretation of these differences is ham-
pered by the considerable systematic differences between the regions in the patterns of disease,
antimicrobial resistance and population structure. In this study, we demonstrated that having
data on a few easily collected variables related to patient and treatment characteristics, it is pos-
sible to develop a risk adjustment model to produce adjusted pCA exposure rates, thereby
Table 3. Overall proportions of treated patients within predefined group and the expected rate of exposure to pediatric reserve antibiotics (pCAs).
Patient group Total patients (n) % in group Exposed to pCAs (n) % Exposed 95% CI
1 Neonatal early onset sepsis 123 10% 2 1.6% 0.2 to 5.8
2 CA sepsis/BSI in otherwise healthy infants and children 251 20% 17 6.8% 4.0 to 10.6
3 CA sepsis/BSI in infants and children with underlying disease 295 23% 60 20.3% 15.9 to 25.3
4 Empiric treatment of HA sepsis/BSI outside of PICU 327 25% 162 49.5% 44.0 to 55.1
5 Targeted treatment of HA sepsis/BSI outside of PICU 173 13% 120 69.4% 61.9 to 76.1
6 HA sepsis/BSI on PICU 112 9% 84 75.0% 65.9 to 82.7
1281 445 34.7%
CA: community-acquired, HA: hospital-acquired, BSI: bloodstream infection, PICU: pediatric intensive care unit.
https://doi.org/10.1371/journal.pone.0199878.t003
Table 4. Distribution of included patients for 6 predefined groups by region.
Patient group Subregion
Africa Asia Australia Northern
Europe
Southern
Europe
Western
Europe
Latin
America
North
America
n % n % n % n % n % n % n % n %
1 Neonatal early onset sepsis 17 10.3 12 6.1 10 16.7 43 13.0 18 7.1 18 10.7 0 0 5 11.6
2 CA sepsis/BSI in otherwise healthy infants and children 38 23.0 24 12.2 14 23.3 64 19.4 70 27.6 28 16.6 1 2.2 4 9.3
3 CA sepsis/BSI in infants and children with underlying disease 74 44.9 54 27.4 12 20.0 55 16.7 40 15.8 44 26.0 9 19.6 10 23.3
4 Empiric treatment of HA sepsis/BSI outside of PICU 24 14.6 54 27.4 15 25.0 102 30.9 65 25.6 30 17.8 14 30.4 16 37.2
5 Targeted treatment of HA sepsis/BSI outside of PICU 11 6.7 27 13.7 4 6.7 47 14.2 35 13.8 30 17.8 12 26.1 5 11.6
6 HA sepsis/BSI on PICU 1 0.6 26 13.2 5 8.3 19 5.8 26 10.2 19 11.2 10 21.7 3 7.0
Carbapenem exposure 17 10.3 57 28.9 5 8.3 44 13.3 53 20.9 33 19.5 20 43.5 3 7.0
Glycopeptide exposure 12 7.3 59 30.0 12 20.0 74 22.4 75 29.5 56 33.1 19 41.3 17 39.5
Total n 165 197 60 330 254 169 46 43
CA: community-acquired, HA: hospital-acquired, BSI: bloodstream infection, PICU: pediatric intensive care unit. The proportions refer to contributions of each group
for the region in question.
https://doi.org/10.1371/journal.pone.0199878.t004
Risk-adjusted hospital pediatric antibiotic use
PLOS ONE | https://doi.org/10.1371/journal.pone.0199878 July 6, 2018 9 / 14
allowing a fairer comparison of regions. In addition, the variables could be combined into a
simple patient classification that differentiated various clinical situations in which the expected
pCA exposure rates would be expected to differ. While a risk-adjustment approach based on
logistic regression is preferable for making comparisons against a standard population, the
classification facilitates benchmarking by creating relatively homogenous groups of patients
who would be expected to have similar exposure to pCA due to their clinical circumstances.
When evaluated, both approaches performed well at discriminating between children in terms
of their likely exposure to pCA.
Overall, the average pCA exposure rate was high at 35%. Exposure rates to pCA were higher
among older children, those on PICU, children with underlying disease, and receiving targeted
treatment for hospital-acquired sepsis/bloodstream infection. That targeted treatment was
strongly associated with higher pCA exposure may reflect a high rate of resistant bacteria iden-
tified in those children with culture-confirmed sepsis/bloodstream infection. Given the rep-
orted high rates of antimicrobial resistance in key pathogens globally, but especially in low-
and middle-income countries [26–28], this is a worrying sign of the prevalence of multidrug-
resistant infections, especially among hospital-acquired infections, in this population.
Regional crude prevalence rates varied considerably, the lowest and highest differing by a
factor of 6.5. After adjustment, the prevalence rates varied by a factor of 2.5, demonstrating
that a large proportion of variation arose from differences in the distribution of the measured
patient and prescription characteristics. Previous analyses of case-mix adjustment in bench-
marking of inpatient antibiotic prescribing have used variables that require detailed knowledge
about each patient [7,9] or detailed hospital-level data [8,10,11]. While models based on these
variables may have demonstrated even better discrimination and calibration in this dataset,
Fig 4. Calibration plot for logistic regression classification model of pCA exposure.
https://doi.org/10.1371/journal.pone.0199878.g004
Risk-adjusted hospital pediatric antibiotic use
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the value of our study is to demonstrate that pCA prescribing rates from prevalence surveys
can be adequately risk-adjusted using easily collected variables. The effectiveness of this
approach needs to be replicated in other datasets, and the benefit of including other factors
also needs evaluation. Nonetheless, the results underline the importance of focusing on the
complete and accurate measurement of important patient-level variables and treatment char-
acteristics during data collection to enable optimal utilization of PPS data.
The predefined patient groups based on clinical reasoning proved to have a similar level of
performance to the full logistic regression model. In practice, the application of a logistic
regression model to inform quality improvement at a hospital level could be challenging
because it produces a single composite statistic that describes overall performance. In contrast,
a classification-based approach makes it possible to monitor the prevalence of pCA in distinct
types of patients, for which the action required to tackle above average rates is likely to be dif-
ferent. This has been found to be a key issue in the development and use of classification sys-
tems in other circumstances [15,16]. The clinical logic underpinning the classification gives it
a face-validity that suggests it could be applicable in other situations. But, we recommend that,
before it is adopted for use in other infection syndromes and healthcare settings (e.g. adult
care), its performance is evaluated further using data collected in that setting.
Our analysis has a number of limitations. First, despite this being as far as we are aware the
largest neonatal and pediatric antibiotic prescribing PPS database globally, some regions con-
tributed only a small number of patients. With a larger sample size, we would have been able
to better estimate true differences in regional pCA exposure rates. Sample size limitations will
also impact the application of our approach at hospital-level. Assuming that prescribing prac-
tices remain relatively stable, the pooling of data from several PPS may be one approach to
overcome small sample sizes. Second, we only included prescriptions that were recorded as
being for sepsis/bloodstream infection. Patients in our cohort may have received additional
antibiotics for another indication (e.g. lower respiratory tract infection), which we did not
include in our evaluation. Whether the same risk factors are associated with pCA exposure in
patients treated for other infections needs to be tested. Third, data on the causative organism
in targeted treatment were not recorded. We therefore rely on local contributors having cor-
rectly identified the recorded treatment as the most suitable narrow-spectrum antibiotic
option for the target pathogen. In the future, pCA exposure rates should be interpreted
together with information on actual resistance at patient or aggregate levels [29,30] to gauge
whether pCA exposure levels are high in response to high antibiotic resistance rates or are
mainly driven by prescriber behavior. Fourth, PPS data provides no information on duration
of pCA exposure, which may have an important impact on the volume of pCAs used in a spe-
cific setting. Fifth, our analysis would need to be repeated analyzing data from a variety of hos-
pitals. ARPEC PPS participant centers were predominantly tertiary and/or university
hospitals, and the relevance of our findings for benchmarking involving smaller secondary
hospitals would have to be confirmed. Finally, the cluster sizes of the participating centers
were too small to support a multilevel model with centre as the cluster. Instead, we fitted a ran-
dom-intercept logistic model with subregions to take account into account the hierarchical
structure of the data. This did not change the conclusions about each variable and there was
excellent agreement between the predictions from the two models. We therefore chose to pres-
ent the results from the simpler standard logistic model.
In addition to conventional case-mix adjustment approaches, predefined patient groups,
such as those described in our analysis, enable the generation of aspirational targets for aggre-
gate pCA exposure rates, either in local, regional or national settings. These targets could be
based on current average levels of exposures or be based on expert consensus about desirable
practice. This would allow the comparison of (i) overall standardized exposure rates; (ii)
Risk-adjusted hospital pediatric antibiotic use
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variations in distribution of patient strata; (iii) variations in exposure rates for specific patient
groups. The advantages of this approach is that evaluations of pCA exposure would take into
account key characteristics of the patients and infection episodes that are highly likely to influ-
ence pCA prescribing decisions and as such reflect justified use of these antibiotics. This may
enable identification of specific target areas for intervention, while taking into account that
what is appropriate may differ between facilities and/or regions. For such comparisons and
target setting treatment and patient characteristics need to be captured, as described in this
manuscript and as is standard during point prevalence surveys. Given the good performance
of the logistic regression classification model in our analysis, the level of detail for the variables
included in the ARPEC PPS may be sufficient for evaluations of childhood antibiotic use.
However, additional or different variables are likely to be useful for similar analyses in other
patient groups.
Case-mix adjustment, preferably using a few easy-to-collect patient and prescription char-
acteristics, is key to accurately and fairly comparing prescribing patterns between health care
providers, regional health care administrations and countries. Furthermore, assessing antibi-
otic exposure rates in a clinically relevant manner within homogenous and easily identifiable
patient groups can be a rich source of information about key areas for intervention to improve
antibiotic prescribing. Quality of antibiotic prescribing could then be assessed in such patient
groups using validated indicators. In this way, interventions that will achieve a safe and reason-
able reduction in the use of critically important antibiotics at aggregate level can be defined
and evaluated.
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